r e v i e w
The 'gate control theory' of pain postulates that neural circuits in the CNS dynamically regulate nociceptive signals arising in the periphery of the body. Since its formulation in 1965 (ref. 1) , this theory has provided a framework in which to interpret the actions of central analgesic circuits, such as those recruited during acute stress or placebo responses. Emerging evidence indicates, however, that nociceptive signals may be subject to a dynamic filtering process even before they reach the spinal cord. Primary sensory neurons and the host-defense cells surrounding them release a variety of analgesic factors that control the traffic of nociceptive information to the CNS (Fig. 1) . Lipid-derived mediators are crucial players, albeit not the only ones 2 , in this peripheral gating mechanism. Here we review the properties of endogenous bioactive lipids that modulate pain initiation by interacting with receptor systems on primary sensory afferents and neighboring cells that are not neurons, including macrophages, mast cells and keratinocytes. We also outline stages of tissue injury and inflammation at which these analgesic lipids may intervene and speculate on how their actions might be exploited to discover better medicines for pain.
Proalgesic lipids
The cell bodies of nociceptors-the primary sensory neurons specialized for detecting harmful stimuli-are housed in anatomical structures located outside the CNS, the trigeminal and dorsal root ganglia (DRG), and generate axonal stalks that split into two sets of fibers running in opposite directions. One reaches the skin and most internal organs, with the exception of the brain, where it senses noxious stimuli and converts them into electrical signals. The other set of fibers extends toward the dorsal horn of the spinal cord to form synapses with local neurons, which process the information arriving from the periphery and transmit it to supraspinal sites. Nociceptors are divided into two broad classes with distinct structure and function. ' Aδ' nociceptors, which have medium-sized cell bodies and fastconducting axons, mediate the localized sharp pain sensation that serves as a warning signal of injury. 'C' nociceptors, which have small-diameter cell bodies and slow-conducting axons, convey the poorly localized delayed pain that supports tissue repair by inducing defensive behaviors. Many (but not all) nociceptors are considered to be polymodal because they share the ability to recognize as harmful external inputs of widely different modalities: thermal, chemical and mechanical. At the root of this perceptual flexibility is the existence of multiple nociceptor subclasses, each expressing a distinctive repertoire of membrane ion channels, receptors and intracellular signaling proteins. For example, the presence of cation channels of the transient receptor potential (TRP) family renders nociceptors differentially sensitive to heat (TRPV1), cold (TRPM8) and chemical irritants (TRPA1). After tissue damage, this heterogeneous palette of transduction molecules undergoes profound changes, giving rise to a state of hyperexcitability, called peripheral sensitization, in which non-noxious events are perceived as noxious (allodynia) and mildly noxious events are perceived as highly noxious (hyperalgesia). Sensitization is often accompanied by neurogenic inflammation-a local vasodilatory response caused by release of substance P and calcitonin gene-related peptide (CGRP) from primary afferent terminals-and by activation of a group of primary sensory neurons, called silent nociceptors, that becomes responsive to harmful stimuli only after tissue damage has occurred 3 .
In addition to external stimuli, nociceptors are exquisitely sensitive to endogenous proalgesic (pain-inducing or pain-enhancing) factors that either are quickly released after an injury or are produced more slowly during inflammation, peripheral neuropathy and tumor growth (Fig. 1) . Intracellular nucleotides such as ATP and ADP, which spill out of damaged cells, and peptides such as bradykinin, which is liberated from a plasma globulin during blood clotting, may supply a first wave of proalgesic chemicals by virtue of their ability to activate excitatory receptors on primary afferents. A second, slower wave of sensitizing and proinflammatory agents includes substance P and CGRP, as well as a diverse array of bioactive lipid-derived mediators generated by primary afferents and nearby host-defense cells. The key roles of two such mediators, prostaglandin E 2 (PGE 2 ) and prostacyclin (PGI 2 ), in nociceptor sensitization were first identified in the 1970s (ref. 4) and are now firmly established 5 . PGE 2 and PGI 2 are produced at sites of inflammation and activate specific G proteincoupled receptors on sensory neurons to increase membrane excitability and enhance secretion of substance P and CGRP 6 . The rate-limiting step in this signaling cascade is provided by two functionally similar, but molecularly distinct, enzymes, cyclooxygenase (Cox)-1 and Cox-2, that convert the membrane-derived polyunsaturated fatty acid (PUFA) arachidonic acid into PGH 2 , a common precursor for all prostanoids 7 . By interrupting Cox-1 and Cox-2 activities, nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen suppress primary afferent sensitization and strongly reduce inflammatory pain 4 . In addition to Cox-1 and Cox-2 products, many other lipid molecules formed through enzymatic or nonenzymatic PUFA oxidation are able to excite nociceptors and cause hyperalgesic states. Recently described examples are the hydroxylated derivatives of linoleic acid 8 , hepoxilin A 3 (ref. 9), PGE 2 -glycerol ester 10 and prostamide F 2 α (ref. 11). Other lipid-derived proalgesic agents include lysophosphatidic acid 6 and lysophosphatidylinositol 12 . While the specific functions served by each of these substances are in most cases unclear, the overall significance of lipid-mediated signaling in the induction and maintenance of persistent pain is widely recognized 3 . Research in the last 10 years has unexpectedly revealed, however, the existence of bioactive lipids that contrast the effects of proalgesic agents and modulate pain initiation at sites of injury and inflammation. These analgesic lipid mediators-which include endogenous cannabinoids, lipid-amide agonists of peroxisome proliferator-activated receptor-α (PPAR-α), and various products of oxidative PUFA metabolism (Table 1) play nonredundant roles in the dynamic modulation of peripheral responses to noxious stimuli.
Endogenous cannabinoids: antinociceptive response to injury Neural and non-neural cells in damaged and inflamed tissues produce a family of arachidonic acid derivatives, called endocannabinoids, that suppress sensitization and neurogenic inflammation by activating CB 1 and CB 2 cannabinoid receptors-the same G i/o protein-coupled receptors that are targeted by the ∆ 9 -tetrahydrocannabinol in marijuana 13 .
Cannabinoid receptors. CB 1 receptors are highly expressed in the CNS, where they are concentrated in axon terminals of inhibitory interneurons and excitatory projection neurons 14 25 and acid-sensing ion channels (ASICs) 26 , reduce calcium transients evoked by capsaicin activation of TRPV1 (refs. 24,27) and block nerve growth factor-induced TRPV1 sensitization 28 . Selective CB 1 receptor antagonists (e.g., rimonabant and AM251) prevent these effects [27] [28] [29] . Consistent with those results, in vivo pharmacological studies have demonstrated that cannabinoid agonists suppress nociceptive behaviors and CGRP release in rodents through a peripheral CB 1 -mediated mechanism [30] [31] [32] [33] . The peripheral nature of these actions is strikingly illustrated by results obtained in mutant mice that specifically lack CB 1 in nociceptive neurons 17, 18 . Compared to their wild-type littermates, these mice show decreased sensitivity to the analgesic effects exerted by local or systemic (but not intrathecal) administration of cannabinoid agents. Notably, these mice also display an exaggerated hyperalgesic response to CFA injection, suggesting that CB 1 receptors on primary afferents modulate the initiation of inflammatory pain.
The second cannabinoid receptor subtype, CB 2, has limited structural similarity with CB 1 (the two proteins are only 40% identical) and a distinctive distribution in mammalian tissues 13 . Substantial CB 2 receptor levels are found in cells of hematopoietic origin, including those interacting with primary afferents during tissue injury (e.g., macrophages and mast cells) 20, 34 (Fig. 2) . CB 2 receptors are sparsely expressed in the brain, spinal cord and DRG of healthy rats and mice, but their numbers increase markedly after peripheral nerve damage 35, 36 . For example, ligation of the L5-L6 spinal nerve and transection or compression of the sciatic nerve all heighten CB 2 expression npg r e v i e w in sensory neurons of rodent DRG 37, 38 . Moreover, CB 2 receptors have been identified in TRPV1-positive nociceptive neurons of human DRG, where their expression is also stimulated by nerve damage 39 . In line with these morphological findings, CB 2 activation by selective agonists (e.g., AM1241 and JWH-133) exerts profound antinociceptive effects in animal models of acute, inflammatory and neuropathic pain 36, 40, 41 . That such effects may be primarily due to a peripheral mechanism is not only suggested by the localization of CB 2 receptors, outlined above, but also by experiments showing that administration of CB 2 agonists into the rat paw suppresses hyperalgesia evoked by injection of capsaicin and reduces the response of spinal neurons to mechanical stimulation 42, 43 . Both neural and non-neural cell populations are likely to contribute to these effects, as indicated by the ability of CB 2 agonists to attenuate calcium transients elicited by capsaicin in rat and human DRG neurons 27, 39 , enhance release of β-endorphin from keratinocytes 44 and reduce the secretion of immune mediators from macrophages and mast cells 45 (Fig. 2) .
In addition to CB 1 and CB 2 , endocannabinoid lipids are also known to interact with noncannabinoid sites, such as TRPV1 channels and G protein-coupled GPR55 receptors. These interactions have attracted a great deal of attention and are discussed in several recent reviews 46, 47 , but their relevance to the peripheral control of nociception is still unclear.
Endogenous cannabinoids. The two best-known members of the endocannabinoid family of lipid mediators, anandamide and 2-arachidonoyl-sn-glycerol (2-AG), are produced through distinct biochemical pathways, each starting with the enzyme-mediated hydrolysis of a specific phospholipid precursor in cell membranes 48 .
Anandamide is formed by cleavage of a relatively uncommon and still poorly understood lipid molecule, in which phosphatidylethanolamine (PE) is covalently linked to arachidonic acid through an amide bond (Fig. 3) . In neurons, this reaction is stimulated by calcium ions and is catalyzed by a structurally unique phospholipase D (PLD) that exclusively recognizes N-acyl-substituted PE species 49 . In macrophages, by contrast, the same reaction may occur in two separate steps: a molecularly uncharacterized phospholipase C (PLC) converts N-arachidonoyl-PE into phosphoanandamide, which then loses its phosphate group by the action of a phosphatase 29 . Newly formed anandamide acts near its sites of production, as an autocrine or paracrine messenger (Fig. 2) , and is rapidly eliminated through a process consisting of carrier-mediated transport into cells (the molecular mechanism of which has so far resisted elucidation) 50 followed by intracellular breakdown to arachidonic acid and ethanolamine, catalyzed by the serine hydrolase fatty acid amide hydrolase (FAAH) 48, 49 . Alternatively, anandamide may be directly transformed by Cox-2 (but not Cox-1) into proalgesic prostamides 11 ( Fig. 3) . A novel class of Cox-2 inhibitors that specifically stop this reaction, without affecting the oxygenation of arachidonic acid to prostaglandins, has been recently disclosed 51 .
Inflammation and nerve injury cause marked changes in anandamide mobilization. For example, in mice and rats, intraplantar injection of CFA 17 or ligation of the sciatic nerve increases anandamide levels in the affected paw 40 , whereas tumor implantation in the heel bone 52 or topical skin application of a proinflammatory phorbol ester 53 produce the opposite effect. Notably, alterations in anandamide levels have also been documented in biopsies of human subjects with acute pancreatitis 54 . The molecular mechanisms underlying such Anandamide is generated by hydrolysis of the membrane lipid N-arachidonoyl-phosphatidylethanolamine (NArPE), which is catalyzed in neurons by a phospholipase D that selectively recognizes N-acylated species of PE (NAPE-PLD). The concentrations of NArPE and anandamide are very low in resting neurons but quickly increase in response to neural activity and/or neurotransmitter receptor occupation. In macrophages, activation of TLR4 by the bacterial endotoxin LPS stimulates an as-yet-uncharacterized phospholipase C (PLC), which converts NArPE into phosphoanandamide. This intermediate is dephosphorylated by a phosphatase (P-ase) to form anandamide. Endogenously produced anandamide modulates nociception by binding to CB 1 cannabinoid receptors. In both neurons and macrophages, anandamide is converted into arachidonic acid and ethanolamine by fatty acid amide hydrolase (FAAH), which is selectively blocked by inhibitors such as the O-arylcarbamate derivative URB597. Anandamide can also be transformed by cyclooxygenase-2 (Cox-2) into proalgesic prostamides, a reaction that is prevented by substrate-selective inhibitors such as LM-4131. Non-steroidal anti-inflammatory drugs (NSAIDs) stop the conversion of arachidonic acid into prostaglandins by inhibiting both Cox-1 and Cox-2 activities. (b) 2-Arachidonyl-sn-glycerol (2-AG). G q -coupled receptors and TLR4 stimulate PLC-β, which converts phosphatidylinositol-4,5-bisphosphate (PIP 2 ) into 1,2-diacylglycerol (DAG). DAG is hydrolyzed by diacylglycerol lipase-α (DGL-α) to yield 2-AG, which inhibits nociceptive responses by activating CB 1 and CB 2 receptors. Monoacylglycerol lipase (MGL) terminates 2-AG signaling by hydrolyzing this glycerol ester into arachidonic acid and glycerol. 2-AG and arachidonic acid may be transformed by Cox-1 and/or Cox-2 into various families of proalgesic lipid mediators, which include PGE 2 glycerol ester (derived from 2-AG) and PGE 2 (derived from arachidonic acid).
npg r e v i e w changes are still incompletely understood. Heightened anandamide mobilization may be due to enhanced calcium entry in nociceptors and/or to stimulation of Toll-like receptor-4 (TLR4) in macrophages 29 ( Fig. 2) . TLR4 is a member of the pattern recognition family of receptors, which recognize exogenous pathogen-associated molecules, such as lipopolysaccharide (LPS), as well as endogenous damage-associated molecules, such as uric acid. Conversely, lowered anandamide availability may result from injury-induced changes in FAAH expression. In the DRG of healthy rats, FAAH is localized to small-diameter C nociceptors, but peripheral nerve damage (sciatic nerve axotomy or lumbar spinal nerve transection) induces its ectopic expression in large-diameter sensory neurons 55 . Moreover, growth of painful bone tumors is associated with enhanced FAAH expression in the paw bearing the tumor and the DRG innervating it 24 . This effect, along with a parallel but independent increase in carrier-mediated anandamide uptake by neurons and/or other cells of the DRG 56 , may be responsible for the observed deficit in anandamide mobilization 52 .
Irrespective of the regulatory mechanisms involved, anandamide released at sites of injury may modulate nociceptive signals by activating local CB 1 receptors. Experiments with pharmacological agents that block intracellular FAAH activity support this idea. For example, intraplantar delivery of the brain-penetrant FAAH inhibitor URB597, at doses that presumably do not interfere with FAAH activity in the CNS, reduces mechanically evoked responses of rat spinal neurons through a mechanism that requires CB 1 activation 35 . Furthermore, systemic administration of the peripherally restricted FAAH inhibitor URB937, which selectively interrupts anandamide degradation outside the brain and spinal cord 57 , causes striking anti-hyperalgesic effects in rodent models of visceral and inflammatory pain 57, 58 . Such effects are exclusively dependent on peripheral FAAH blockade and are prevented by the CB 1 antagonists rimonabant and AM251, but not by the CB 2 antagonist AM630 (refs. 57,58). Interestingly, FAAH inhibitors act in a synergistic manner with NSAIDs to attenuate painrelated behaviors elicited, in mice, by carrageenan or sciatic nerve constriction 58, 59 . This superadditive interaction underscores the deep functional links between endocannabinoids and prostanoids, as well as the interest in developing dual inhibitors that target both FAAH and Cox activities.
Unlike anandamide, 2-AG derives from the hydrolysis of a wellknown inositol-containing phospholipid, phosphatidylinositol-4,5-bisphosphate (PIP 2 ), the centerpiece of a lipid pathway that generates several intracellular and transcellular messengers 48 (Fig. 3) . The first reaction in this pathway is catalyzed by the β-isoform of PLC (PLC-β), which is activated by G q -coupled receptors and converts PIP 2 into the second messenger 1,2-diacylglycerol (DAG). DAG regulates protein kinase C and other cellular effectors, but it also serves as substrate for the hydrolytic activity of diacylglycerol lipase-α (DGL-α), which cleaves DAG into 2-AG 48 . The serine hydrolase monoacylglycerol lipase (MGL) is the main enzyme involved in terminating 2-AG-mediated endocannabinoid signaling, which it accomplishes by hydrolyzing this glycerol ester and releasing free arachidonic acid. Like anandamide, 2-AG may be metabolized by Cox-2 to produce proalgesic derivatives such as PGE 2 glycerol ester 10 .
In the brain and spinal cord, 2-AG mobilization is controlled by receptors linked to transducing G q proteins 46, 60 and is crucially involved in the descending modulation of pain during acute stress 61 . Similarly, in cultures of rat DRG neurons, the proalgesic peptide bradykinin causes a rapid release of 2-AG, presumably through activation of B 2 bradykinin receptors 62 , while platelet-activating factor (PAF) produces a similar effect in Raw264.7 macrophages by engaging PAF receptors 63 . In addition to these G q -mediated responses, generation of 2-AG may be initiated, in rat platelets, by TLR4 activation 64 . Mechanisms such as those described above probably underlie the localized increase in 2-AG observed in CFA-inflamed mouse paws 17 . The relevance of localized 2-AG release to nociceptive signaling is confirmed by the finding that intraplantar injections of MGL inhibitors (URB602 or JZL-184) counteract the pain-related behaviors evoked by formalin administration in rats 65 or tumor growth in mice 52 . The dependence of these effects on CB 2 receptor activity 52,66 distinguishes MGL inhibitors from FAAH inhibitors and indicates that 2-AG and anandamide may influence pain initiation through complementary, rather than overlapping, mechanisms (Fig. 3) .
In summary, many lines of evidence suggest that endocannabinoid lipids are rapidly recruited during tissue injury to provide a first line of control over arising nociceptive signals. The therapeutic opportunity offered by this peripheral gating mechanism-the possibility of achieving effective analgesia without causing untoward central effects-has fueled intensive efforts to discover new agents that influence endocannabinoid signaling outside the CNS ( Table 2) . Such efforts are not without challenges, however. Among the problems to be faced are the selection of specific endocannabinoid mechanisms that must be targeted to achieve adequate analgesic efficacy (e.g., peripheral CB 1 versus CB 2 agonism, global versus peripheral FAAH inhibition), and the identification of clinical pain conditions that would most likely respond to pharmacological interference with those mechanisms.
Endogenous PPAR-α agonists: homeostatic nociception control PPAR-α is a ligand-operated transcription factor that plays essential roles in energy metabolism and inflammation 67 . An unusually spacious ligand-binding pocket allows this receptor to recognize, albeit with different affinities, a variety of endogenous fatty-acid derivatives. These include low-potency agonists (e.g., free fatty acids), which act at mid-micromolar to high-micromolar concentrations 68 , and high-potency agonists (e.g., 8(S)-hydroxyeicosatetraenoic acid and amides of ethanolamine with saturated and monounsaturated fatty acids (FAE)), which act at submicromolar to single-digit micromolar concentrations [69] [70] [71] . The FAEs, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) (Fig. 4) , engage PPAR-α with median effective concentration (EC 50 ) 0.12 µM for OEA and 3 µM for PEA 69, 70 , have emerged as potential homeostatic regulators of nociception.
Peroxisome proliferator-activated receptor-α. Like other members of the nuclear receptor superfamily, PPAR-α is activated through ligand binding, which causes the formation of a multiprotein complex that comprises an obligatory partner, the retinoid X receptor (RXR), along with a variable set of protein coactivators 67 . In its active form, PPAR-α binds to responsive elements on DNA, enhancing the transcription of various anti-inflammatory proteins, such as inhibitor of κB-α (IκB-α), while concomitantly interrupting the activity of proinflammatory transcription factors through direct protein-protein interactions (a process called transrepression) 67 . Transcriptional regulators modulated by PPAR-α include nuclear factor κB (NF-κB), signal transducers and activators of transcription (STATs), activator protein 1 (AP1) and nuclear factor of activated T cells (NFAT) 67 . In addition to inducing changes in gene expression, which unfold over a period of hours or even days, PPAR-α activation may also produce rapid, nongenomic effects, as briefly discussed below.
PPAR-α is expressed in many organs and tissues 67 , including DRG neurons 72 , macrophages 67 and other host-defense cells 67, 73 . Consistent with this localization, local or systemic administration of npg r e v i e w synthetic PPAR-α agonists (e.g., GW7647 and Wy-14643) exerts profound anti-inflammatory effects in mice 70, 74, 75 , suppresses pain-related behaviors elicited in rats and mice by injection of carrageenan, formalin or magnesium sulfate 72, 74 , and prevents formalin-induced firing of rat spinal cord neurons 72 . The endogenous PPAR-α agonist PEA has similar anti-hyperalgesic properties, which are synergistic with those of CB 1 receptor agonists 30, 72, 76 . Additionally, PPAR-α activation strongly reduces thermal and mechanical hyperalgesia evoked in mice by nerve injury (constriction of the sciatic nerve) or inflammation (CFA injection) 72 . These anti-hyperalgesic effects are absent in PPAR-α−deficient mice 72 , which also show enhanced responses to several proinflammatory and proalgesic stimuli 77, 78 , an important indication that PPAR-α participates in the tonic control of inflammation and nociception.
The analgesic actions of PPAR-α ligands appear within minutes of drug administration, suggesting that they may be mediated, at least initially, by a transcription-independent mechanism. In support of this idea, studies with selective inhibitors have identified two subtypes of calcium-activated potassium channels that may be rapidly regulated by PPAR-α: largeconductance BK Ca (K Ca 1.1) and intermediate-conductance IK Ca (K Ca 3.1) channels 72 ( Fig. 5) . BK Ca and IK Ca channels are known to modulate the excitability of primary sensory neurons 79 , but the molecular steps connecting PPAR-α activation to the gating of these channels remain to be defined. Anti-hyperalgesic activity may also result from the interaction of PPAR-α with transcription factors of the NF-κB complex, which suppress the expression of genes targeted by immune-derived proalgesic mediators, including tumor necrosis factor-α (TNF-α) and interleukin-1β (Fig. 5) . Lastly, it is worth noting that PPAR-α agonists can also attenuate hyperalgesia after infusion into the cerebral ventricles 80 . This finding underscores a growing awareness of the role of the PPAR family of receptors (PPAR-γ along with PPAR-α) in the central modulation of pain signals 81 .
Endogenous agonists of PPAR-α. OEA and PEA are chemically related to anandamide and, in neurons, are produced by the activity of the same PLD that catalyzes anandamide release 82 (Fig. 4) . Nevertheless, the mechanisms governing the formation of these FAEs differ from those involved in the production of anandamide in two important respects. First, many cell types in the body, including DRG neurons and skin cells, generate substantial amounts of OEA and PEA even in the absence of external The current therapy of chronic pain relies heavily on opiates (e.g., morphine and oxycodone) and anticonvulsants (e.g., gabapentin and pregabalin), two classes of drugs that primarily act on neural circuits of the brain and spinal cord. These agents help many, but their use is associated with central side effects and abuse potential. The existence of peripheral lipid-mediated mechanisms that regulate the flow of nociceptive signals to the CNS offers the opportunity to develop medications that control pain without producing undesired central effects. Activation of CB 1 cannabinoid receptors in the brain is psychotropic, but peripherally restricted CB 1 agonists or globally active CB 2 agonists (e.g., AM1241) reduce nociceptive responses in rodent models without eliciting overt signs of cannabinoid intoxication. Marked antinociceptive actions, mediated by CB 1 and/or CB 2 receptors, are also observed with inhibitors of the endocannabinoid-hydrolyzing enzymes fatty acid amide hydrolase (FAAH; e.g., URB597 or URB937) and monoacylglycerol lipase (MGL; e.g., JZL184). PPAR-α-mediated antinociception can be achieved either using direct PPAR-α agonists, such as the endogenous ligand palmitoylethanolamide (PEA), or inhibitors of the PEA-hydrolyzing enzyme N-acylethanolamine acid amidase (NAAA; e.g., ARN077). Similar approaches may be used to exploit the analgesic properties of endogenous bioactive lipids generated by oxygenation of polyunsaturated fatty acids (PUFAs): inhibition of soluble epoxide hydrolase (sEH), which converts epoxygenated PUFAs into inactive dihydroxy acids, and administration of resolvins both produce marked antinociception in rodent models.
npg r e v i e w stimuli, which are required instead to trigger on-demand anandamide release. Because of this tonic production, the levels of OEA and PEA in healthy tissues are much higher than those of anandamide. For example, the baseline concentration of PEA in mouse ear skin is approximately 3.5 µM, more than 175 times greater than that of anandamide 53 . Thus, on the basis of the known affinities of PPAR-α for OEA and PEA (EC 50 , 0.12-3 µM), it is reasonable to assume that a substantial fraction of PPAR-α is constitutively bound to FAEs in unstimulated cells. Second, many proinflammatory stimuli dampen the production of OEA and PEA even as they trigger anandamide formation in the same cell. For example, macrophages exposed to the bacterial toxin LPS respond with a rapid burst of anandamide release 29 , followed by a slower persistent decrease in FAE content 83, 84 . Experiments with Raw264.7 macrophages suggest that the PLC-phosphatase pathway mediates the initial spike in anandamide production 29 (Fig. 3) , whereas the delayed decline in OEA and PEA results from a downregulation in transcription of a phospholipase D that selectively recognizes N-acylated species of PE (NAPE-PLD) as a result of reduced acetylation of histone proteins bound to the Napepld promoter 84 . The ability of tissue damage to suppress FAE mobilization has been documented using multiple animal models of inflammation and peripheral neuropathy 53, 56, 70, 83 . Adding clinical relevance to these observations, one study found that the concentrations of OEA and PEA in synovial fluid are lower in subjects with rheumatoid arthritis and osteoarthritis than in healthy controls 85 . The results outlined above suggest that endogenous FAE signaling at PPAR-α exerts a tonic inhibitory control over the induction of inflammatory and nociceptive responses. This idea was tested using pharmacological agents that selectively block the cysteine hydrolase N-acylethanolamine acid amidase (NAAA) 53, 56, 83 , which catalyzes the deactivating hydrolysis of OEA and PEA in macrophages 49 (Fig. 4) . Topical administration of the NAAA inhibitor N-[(3S)-2-oxo-3-oxetanyl]-3-phenylpropanamide in mice reinstates normal PEA levels in activated leukocytes and blunts inflammatory responses induced by LPS or carrageenan 83 . Exogenous PEA mimics these effects, while PPAR-α deletion abolishes them. Under the same conditions, the FAAH inhibitor URB597 fails to normalize PEA levels, highlighting the critical role of NAAA in PEA and OEA degradation by innate immune cells. A second NAAA inhibitor, the compound ARN077, attenuates heat hyperalgesia and mechanical allodynia elicited in mice and rats by carrageenan injection, sciatic nerve ligation or ultraviolet B radiation 53 . These antinociceptive effects are absent in PPAR-α-deficient mice and are prevented, in rats, by the PPAR-α antagonist GW6471. Similarly, ARN077 reduces mechanical hyperalgesia in fibrosarcoma-bearing mice and corrects, through a mechanism mediated by PPAR-α, abnormal calcium signaling in DRG neurons cocultured with fibrosarcoma cells 86 . Confirming its proposed mechanism of action, ARN077 restores baseline FAE levels in diseased tissues of neuropathic and tumorbearing mice 53, 86 .
To sum up, a plausible interpretation of the available data is that endogenous FAEs acting at PPAR-α help maintain host-defense homeostasis by preventing the launch of inappropriate inflammatory and nociceptive reactions (Fig. 5) . Thus, the function of these lipid mediators may be compared to that of an electronic high-pass filter, which attenuates signals that fail to reach a set threshold. Two strategies may be used to exploit this mechanism for therapeutic purposes ( Table 2 ). The first is to directly activate PPAR-α using synthetic or endogenous ligands 67, 76 . Though theoretically possible, this approach is riddled with practical problems owing to the safety risks posed by excessive directagonist activation of PPAR-α 87 and the inherent complexity of adapting natural lipid molecules to therapeutic usage (e.g., quick metabolism, high plasma protein binding, low solubility). An alternative strategy is to create small drug-like molecules that enhance intrinsic PPAR-α signaling by interrupting the NAAA-mediated degradation of OEA and PEA 53, 83, 86 . Since the main effect of NAAA inhibitors is to normalize FAE signaling in injured or inflamed tissues, rather than to indiscriminately activate PPAR-α throughout the body, this approach may offer a degree of cellular selectivity that might translate into greater efficacy and safety.
PUFA oxygenation products and nociceptive homeostasis
The lipid profile of an exudate-the fluid that filters from the blood into a site of inflammation-undergoes dramatic changes in the course of a self-limited inflammatory reaction. As this reaction phases out into resolution, the initial complement of potent proalgesic and proinflammatory lipid mediators, prostanoids such as PGE 2 and PGI 2 and leukotrienes such as LTB 4 , is replaced by a different set of lipid molecules that promote the return of the inflamed tissue to homeostasis by stopping neutrophil infiltration, accelerating the clearance of cellular debris, enhancing the antimicrobial activity of epithelial cells and stimulating wound healing 88 . As part of their effort to restore homeostasis, these bioactive lipids may also normalize nociceptive Epoxygenated fatty acids. The cytochrome P 450 family of enzymes catalyzes the oxygenation of various long-chain PUFAs, including arachidonic acid, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), each giving rise to a distinct group of bioactive epoxidecontaining fatty acids (EpFAs), which act near their site of synthesis to regulate vascular tone, kidney function and inflammation 89 (Fig. 6) . The EpFAs are quickly converted by the enzyme soluble epoxide hydrolase (sEH) into 1,2-dihydroxy fatty acids, which are either less active or have different activities than the parent molecules. The discovery of potent and selective inhibitors of intracellular sEH activity has allowed researchers to explore the functions of endogenously produced EpFAs in animal models of inflammatory and neuropathic pain. These investigations have shown that systemic administration of sEH inhibitors or local injection of synthetically prepared EpFAs attenuate pain-related responses evoked by LPS or carrageenan in rats 89 . A more recent study has examined the impact of three structurally different sEH inhibitors in rats rendered hypersensitive to pain stimuli by treatment with streptozotocin, a toxin that causes type-1 diabetes by selectively killing insulin-secreting β-cells in the pancreas 90 . The inhibitors reduce mechanical allodynia in streptozotocin-treated rats, without influencing normal nociceptive responding in healthy animals, and concomitantly increase unmetabolized EpFAs in plasma and spinal cord. Even though the receptor(s) responsible for these effects are still unknown, the marked antihyperalgesic properties of sEH inhibitors support a role for endogenous EpFAs in the modulation of nociceptive signaling and identify sEH as a potential target for analgesic drugs 89 ( Table 2) .
Lipoxins, resolvins and allied compounds. The lipoxins are generated through the sequential enzyme-mediated oxygenation of membrane-derived arachidonic acid 88 (Fig. 6) . Their biosynthetic routes are multiple and complex, and have been reviewed in detail elsewhere 91 . One important point to mention here is that several key pathways of lipoxin biosynthesis involve the cooperation among different cell types that contact one another during an inflammatory response. For example, neutrophils produce lipoxin A 4 (LXA 4 ), one of the best-known members of this class, utilizing as substrate a short-lived metabolite of arachidonic acid released from nearby macrophages 88 . This unusual mode of production, called transcellular biosynthesis, reflects the physiological need to match the complement of bioactive lipid mediators present at an inflammatory site with the varying cellular profiles progressively recruited to that site. The anti-inflammatory and pro-resolution effects of In the absence of stimulation, macrophages and DRG neurons produce substantial amounts of OEA and PEA from their respective N-acyl phosphatidylethanolamine (NAPE) precursors. These fatty acid ethanolamides (FAEs) exert a tonic inhibitory control over macrophage activity and nociceptor excitability by recruiting PPAR-α-dependent mechanisms, which may include opening of large-conductance (BK Ca ) and intermediate-conductance (IK Ca ) potassium channels and regulation of the NF-κB transcription complex (composed of p50, p65 and inhibitor of κB-α (IκB-α)). After tissue damage or during inflammation, microbial toxins, such as LPS, and/or immune-derived cytokines, such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), suppress FAE biosynthesis and stop FAE signaling at PPAR-α, temporarily disabling its inhibitory function. These molecular events may take place both in neurons and other cells of the DRG (a) and in peripheral nerve endings of primary sensory neurons (b). In the periphery, FAEs may also influence tissue repair, by engaging PPAR-α in keratinocytes, and mast cell degranulation, possibly by interacting with G protein-coupled GPR55 receptors. FcεRI, high affinity immunoglobulin E receptor; NFκBRE, NF-κB responsive elements; TLR4, Toll-like receptor-4.
npg r e v i e w LXA 4 are mediated by G protein-coupled ALX/FPR2 receptors (also called formyl peptide receptor-like 1, FPRL-1) 88 , but the attenuated nociception that accompanies such effects might also involve CB 1 cannabinoid receptors. Pharmacological studies suggest that LXA 4 acts as a positive allosteric CB 1 modulator, potentiating CB 1 -mediated responses evoked by anandamide in vitro and in vivo and increasing the ability of this compound to displace the binding of a radiolabeled CB 1 ligand to mouse brain membranes 92 .
Resolvins and protectins are produced, like the lipoxins, through the multistep oxygenation of membrane-derived PUFAs; however, they do not utilize as precursor arachidonic acid, an ω6 PUFA, but rather the ω3 PUFAs EPA and DHA (Fig. 6) . EPA gives rise to E-series resolvins such as resolvin E 1 (RvE 1 ), while DHA is converted into D-series resolvins such as resolvin D 1 (RvD 1 ), as well as protectin D 1 (ref. 91) . Additionally, in human macrophages and platelets, DHA may be transformed by 12-lipoxygenase to form maresin 1 (Fig. 6) 91 . The pro-resolving and immune-modulating properties displayed by these bioactive lipids are impressive 88 , but they are not sufficient to explain the array of antinociceptive effects exerted by some of them. For example, intraplantar administration of RvE 1 or RvD 1 in mice suppresses pain-related responses evoked by a broad variety of proalgesic stimuli, including formalin, capsaicin, CFA, TNF-α and PGE 2 (refs. 93,94) . RvE 1 and RvD 1 are also highly effective at reducing nociceptive behaviors caused by skin incision or muscle retraction in mice and rats, two models of human postoperative pain 94 . The receptor mechanisms that mediate these analgesic actions are only partially understood. There is evidence that the G i -coupled receptor chemerin receptor-23 (ChemR23), which also binds the adipokine chemerin, is involved in the effects of RvE 1 . This idea is consistent with the presence of ChemR23 in DRG neurons and the ability of chemerin to mimic the antinociceptive actions of RvE 1 (ref. 93) . RvD 1 activates the LXA 4 receptor, ALX/FPR2, but the functional significance of this interaction is still unclear 95 .
With their high pharmacological potencies and short life spans, lipoxins, resolvins and allied molecules fit the profile of 'soft drugs': agents that undergo quick and predictable deactivating metabolism after having accomplished their therapeutic goal. Not surprisingly, therefore, pharmaceutical development in this area is focused on the use of resolvin analogs for the topical treatment of localized inflammatory conditions, such as dry eye. Nevertheless, there may be several pain-related applications for resolvin-based soft drugs, including the intra-articular treatment of pain arising from knee surgery or osteoarthritis.
Conclusions
The evidence presented here allows us to conjecture that bioactive lipid mediators regulate the access of nociceptive information to the CNS at three distinct stages. In healthy tissues, the tonic release of endogenous PPAR-α agonists, such as PEA and OEA, may help set the threshold for nociception by regulating the baseline transcriptional activity of the NF-κB complex and the opening of membrane ion channels in primary sensory afferents and nearby host-defense cells. After an injury has occurred, the temporary interruption of OEA and PEA biosynthesis caused by cell damage and infection may disable the inhibitory influence exerted by these lipid messengers, allowing inflammation to unfold and nociceptive thresholds to decrease. At the same time, the localized on-demand formation of endocannabinoids such as anandamide may mitigate the effects of exogenous and endogenous proalgesic agents by attenuating nociceptor excitability and counteracting local proinflammatory signals. Lastly, as the response to tissue damage moves toward its resolution phase, a wave of analgesic products of oxidative PUFA metabolism, including lipoxins and resolvins, may help normalize nociceptive responses in the healing tissue. It is likely, but remains to be proven, that the correct deployment of this signaling program is subject to local and systemic regulatory mechanisms. At the local level, lipid mediators released in the early phases of injury may govern the generation of substances acting at later stages: this has been demonstrated for pro-resolving lipoxins, for example, the production of which is partly controlled by proalgesic Cox-2-derived prostaglandins 88 . At the system level, neural npg r e v i e w and hormonal signals may help integrate peripheral and central gating mechanisms during conditions of altered nociception, such as acute stress or body-wide inflammation. The autonomic nervous system, which modulates the biosynthesis of endogenous PPAR-α agonists in some peripheral tissues (e.g., white adipose) 96 , might be important in this context 97 . In addition to addressing such issues, future studies will also need to determine whether errors in the correct unfolding of the intrinsic analgesic pathways outlined here might contribute to the development and maintenance of pathological pain states. Aided by continuing advances in mass spectrometry-based lipidomics, such studies may lead to the discovery of novel analgesic lipids and the development of innovative medicines that effectively control pain without interfering with central neurotransmission.
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